selected scholarly activity
-
conferences
- Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis. Dermatology and Therapy. 1917-1928. 2024
- Real-World Effectiveness and Safety of Risankizumab in Adult Patients with Plaque Psoriasis: A 16-Week International Multicenter Retrospective Cohort Study.. Journal of Cutaneous Medicine and Surgery. 604-605. 2024
- Long-term efficacy and safety of guselkumab in psoriasis patients with and without psoriatic arthritis: A pooled analysis from VOYAGE 1 and VOYAGE 2. Journal of American Academy of Dermatology. AB233-AB233. 2019
- Impact of Guselkumab Versus Placebo and Adalimumab on Patient Reported Outcomes in Patients with and without Psoriatic Arthritis in a Phase 3 Pivotal Psoriasis Study. Arthritis & Rheumatology. 2018
- Secukinumab demonstrates significant improvement of disease activity and health-related quality of life in Canadian psoriasis patients in a real-world setting. Journal of American Academy of Dermatology. AB256-AB256. 2018
- Sociodemographic and baseline disease profile of patients with moderate to severe chronic plaque psoriasis treated with secukinumab vs. other treatments in Canadian routine clinical care: Results from the PURE registry. Journal of American Academy of Dermatology. AB265-AB265. 2018
- AB0939 Off-label secukinumab dose escalation in the treatment of moderate-to-severe psoriasis: a multicenter, retrospective study. Annals of the Rheumatic Diseases. 1594-1594. 2018
- Continuous treatment with secukinumab 300 mg demonstrates sustained efficacy in clearing skin, and improving patient-reported outcomes in moderate-to-severe plaque-psoriasis: Two-year results from the CLEAR-study. Australasian Journal of Dermatology. 112-112. 2018
- IXEKIZUMAB IMPROVES PATIENT-REPORTED OUTCOMES THROUGH 52 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR-INHIBITORS. Internal Medicine Journal. 39-40. 2018
- IMPACT OF GUSELKUMAB VERSUS PLACEBO AND ADALIMUMAB ON PATIENT REPORTED OUTCOMES IN PATIENTS WITH AND WITHOUT PSORIATIC ARTHRITIS IN VOYAGE 2. Acta Dermato-Venereologica. 50-51. 2018
- PATIENT EXPECTATIONS AND SATISFACTION IN PSORIASIS TREATMENT: A SURVEY FROM EUROPE AND CANADA. Acta Dermato-Venereologica. 34-34. 2018
- Ixekizumab Improves Patient-Reported Outcomes through 52 Weeks in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to Tumor Necrosis Factor-Inhibitors. Arthritis & Rheumatology. 2017
- Comparison of Baseline Characteristics of Psoriatic Arthritis Patients Initiating Therapy with Subcutaneous Golimumab or Ustekinumab: An Analysis from a Prospective, Observational Registry. Journal of Rheumatology. 918-919. 2017
- Early real-world effectiveness of secukinumab in the treatment of psoriasis in Canada: Retrospective analysis of patient support program data. Journal of American Academy of Dermatology. AB107-AB107. 2017
- SAT0446 Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and previous inadequate response to tumour necrosis factor-inhibitors. Annals of the Rheumatic Diseases. 941-941. 2017
- Secukinumab provides greater 52-week sustained relief from dermatology-related quality of life impact on clothing choice and sexual function than ustekinumab. Journal of American Academy of Dermatology. AB230-AB230. 2017
- Secukinumab provides greater cumulative 52-week skin clearance and quality of life benefit in patients with moderate-to-severe plaque psoriasis than ustekinumab: An area under the curve analysis. Journal of American Academy of Dermatology. AB231-AB231. 2017
- Comparison of guselkumab with placebo and adalimumab on health-related quality of life in a phase 2b clinical trial X-PLORE. Journal of American Academy of Dermatology. AB241-AB241. 2016
- Secukinumab shows sustained response in subjects with moderate-to-severe plaque psoriasis: a subanalysis of the ERASURE phase 3 study. Australasian Journal of Dermatology. 83-83. 2015
- Psoriasis, sleep and interleukin-17: is it a reality or just a dream?. British Journal of Dermatology. E130-E131. 2014
- Nonmelanoma skin cancer in Canada. British Journal of Dermatology. 48-49. 2014
- Nonmelanoma skin cancer in Canada. British Journal of Dermatology. E60-E61. 2014
- Topical fixed-dose adapalene/benzoyl peroxide plus oral doxycycline: An evidence-based alternative to oral Isotretinoin in the treatment of severe nodular acne. Australasian Journal of Dermatology. 35-36. 2014
- Comparison of Dermatologists' and Nondermatologists' Diagnostic Accuracy for Malignant Melanoma. Journal of Cutaneous Medicine and Surgery. 272-280. 2012
- Ustekinumab demonstrates rapid onset of efficacy in the treatment of moderate-to-severe psoriasis. Journal of the European Academy of Dermatology and Venereology. 18-18. 2010
- Efalizumab's effectiveness in treating plaque psoriasis affecting the hands/feet, scalp, and nails: Interim subanalysis of the Canadian RESTORE study data. Journal of American Academy of Dermatology. AB182-AB182. 2009
- A practical understanding of mean percent PASI reduction for biologics. Journal of American Academy of Dermatology. AB5-AB5. 2008
- Infliximab-induced pustular psoriasis. Journal of American Academy of Dermatology. AB125-AB125. 2008
- Palmoplantar keratoderma in a patient with a chromosome 12q deletion. Journal of American Academy of Dermatology. AB80-AB80. 2008
- Similar responses with adalimumab therapy in patients with moderate versus severe psoriasis: Subanalysis of multiple placebo-controlled trials. Journal of American Academy of Dermatology. AB128-AB128. 2008
-
journal articles
- A systematic review of recent randomized controlled trials for palmoplantar pustulosis.. Journal of Dermatological Treatment. 35:2414048. 2024
-
Age affects drug survival rates of interleukin (
IL )‐17 andIL ‐23 inhibitors in patients with plaque psoriasis: Results from a retrospective, multicentric, multi‐country, cohort study. Journal of the European Academy of Dermatology and Venereology. 38:2175-2185. 2024 - Effectiveness and safety of risankizumab dose optimization in adult patients with plaque psoriasis: An international multicentre retrospective cohort study.. Journal of the European Academy of Dermatology and Venereology. 2024
- Considerations for defining and diagnosing generalized pustular psoriasis.. Journal of the European Academy of Dermatology and Venereology. 2024
- Underreporting of sleep variables in psoriasis clinical trials. JEADV Clinical Practice. 3:1306-1307. 2024
- Predicting psoriasis severity using machine learning: A systematic review.. Clinical and Experimental Dermatology. llae348. 2024
- Morphea in patients with psoriasis treated with ustekinumab: a scoping review. Archives of Dermatological Research. 316:492. 2024
- An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis. New England Journal of Medicine. 390:510-521. 2024
- Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor). Dermatology and Therapy. 14:441-451. 2024
- Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents. Pharmaceutics. 16:111-111. 2024
- Association Between Parkinson’s Disease and Psoriasis: A Scoping Review. Journal of Cutaneous Medicine and Surgery. 28:72-73. 2024
- Evaluation of Vision LLMs GTP-4V and LLaVA for the Recognition of Features Characteristic of Melanoma. Journal of Cutaneous Medicine and Surgery. 28:98-99. 2024
- GLP-1R Agonists in Psoriasis Patients. Journal of Cutaneous Medicine and Surgery. 28:91-92. 2024
- Management of Guttate Psoriasis: A Systematic Review. Journal of Cutaneous Medicine and Surgery. 28:577-584. 2024
- Use of Janus Kinase Inhibitor Treatment for Palmoplantar Pustulosis: An Evidence-Based Review. Journal of Cutaneous Medicine and Surgery. 28:86-87. 2024
- Research productivity among Canadian first year dermatology residents: A 15 year analysis. JAAD Int. 13:181-183. 2023
- Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal of Cutaneous Medicine and Surgery. 27:594-600. 2023
- Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse). British Journal of Dermatology. 189:540-552. 2023
- Topical roflumilast for the treatment of psoriasis. Expert Review of Clinical Immunology. 19:1053-1062. 2023
- Speed of clinical improvement in the real‐world setting from patient‐reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks. Journal of the European Academy of Dermatology and Venereology. 37:1825-1840. 2023
- Correction to: Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatology and Therapy. 13:1889-1890. 2023
- Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatology and Therapy. 13:1891-1892. 2023
- Management of adult generalized pustular psoriasis using biologics: A systematic review. Journal of American Academy of Dermatology. 89:417-419. 2023
- A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections. Journal of Cutaneous Medicine and Surgery. 27:358-367. 2023
- Viewpoint about biologic agents for psoriasis: are they immunosuppressants or immunomodulators?. Journal of International Medical Research. 51:3000605231175547. 2023
- Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatology and Therapy. 13:867-889. 2023
- Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial. British Journal of Dermatology. 188:22-31. 2023
- Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway. Journal of Cutaneous Medicine and Surgery. 27:3S-24S. 2023
- Plaque psoriasis and morphea in a patient on ustekinumab: A case report. SAGE Open Medical Case Reports. 11:2050313X2311642-2050313X2311642. 2023
- Quality of Life and Body Region Affected by Psoriasis: A Systematic Review. Actas Dermo-Sifiliograficas. 114:33-38. 2023
- Under-Reporting of COVID-19 Infections in Psoriasis Patients on Biologics. Journal of Cutaneous Medicine and Surgery. 27:75-76. 2023
- [Artículo traducido] Calidad de vida y región corporal afectada por la psoriasis: una revisión sistemática. Actas Dermo-Sifiliograficas. 114:T33-T38. 2023
- A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians. Dermatology and Therapy. 12:2715-2730. 2022
- Management of pediatric generalized pustular psoriasis using biologics: An evidence-based review. Journal of American Academy of Dermatology. 87:484-486. 2022
- Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study. Journal of Dermatological Treatment. 33:2692-2694. 2022
- Review and Practical Guidance on Managing Fungal Infections in Patients With Psoriasis Receiving Anti-IL-17 Therapies. Journal of Cutaneous Medicine and Surgery. 26:3S-23S. 2022
- Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers. Journal of Cutaneous Medicine and Surgery. 26:267-273. 2022
- Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study. Journal of Cutaneous Medicine and Surgery. 26:319-320. 2022
- Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatology and Therapy. 12:1073-1089. 2022
- Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study. JAAD Int. 6:3-5. 2022
- Incidence and prognosis of COVID‐19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study. Journal of the European Academy of Dermatology and Venereology. 36:e94-e95. 2022
- Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology. Dermatology and Therapy. 12:253-265. 2022
- A Useful Clinical Tool for Psoriasis. Journal of Cutaneous Medicine and Surgery. 25:648-649. 2021
- Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab. British Journal of Dermatology. 185:865-867. 2021
- Incidence and prognosis of COVID‐19 in psoriasis patients on biologic therapy: a multicentre retrospective cohort study. Journal of the European Academy of Dermatology and Venereology. 35:e485-e487. 2021
- A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*. British Journal of Dermatology. 184:1047-1058. 2021
- Psoriasis Prevalence and Severity by Expert Elicitation. Dermatology and Therapy. 11:1053-1064. 2021
- A Psoriatic Patient-Based Survey on the Understanding of the Use of Vaccines While on Biologics During the COVID-19 Pandemic. Journal of Cutaneous Medicine and Surgery. 25:298-302. 2021
- Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors. Journal of American Academy of Dermatology. 84:1169-1171. 2021
- Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. Journal of the European Academy of Dermatology and Venereology. 35:797-806. 2021
- Lessons From the First Wave of the Pandemic: Skin Features of COVID-19 Can Be Divided Into Inflammatory and Vascular Patterns. Journal of Cutaneous Medicine and Surgery. 25:169-176. 2021
- Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. The Lancet. 397:475-486. 2021
- A Review of Drug-Drug Interactions for Biologic Drugs Used in the Treatment of Psoriasis. Journal of Cutaneous Medicine and Surgery. 25:38-44. 2021
- A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab. Frontiers in Medicine. 8:702776. 2021
- Guselkumab dosing interval optimization in adult patients with psoriasis: A retrospective, multicenter case series. Journal of American Academy of Dermatology. 83:1813-1814. 2020
- The Incidence and Prevalence of Uveitis in Psoriasis: A Systematic Review and Meta-Analysis. Journal of Cutaneous Medicine and Surgery. 24:601-607. 2020
- Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper. Journal of Cutaneous Medicine and Surgery. 24:3S-14S. 2020
- Patient-Driven Discontinuation of Apremilast During the COVID-19 Pandemic in Two Canadian Academic Hospital Clinics and One Community Practice. Journal of Cutaneous Medicine and Surgery. 24:418-419. 2020
- A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial. British Journal of Dermatology. 182:1348-1358. 2020
- Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study. Journal of American Academy of Dermatology. 81:1405-1409. 2019
- The Role of IL-17 in Papulopustular Rosacea and Future Directions. Journal of Cutaneous Medicine and Surgery. 23:635-641. 2019
- Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis. BioDrugs. 33:391-399. 2019
- Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis. Journal of Cutaneous Medicine and Surgery. 23:391-393. 2019
-
Granulocyte–macrophage colony‐stimulating factor (
GM ‐CSF ) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐GM ‐CSF monoclonal antibody. British Journal of Dermatology. 180:1352-1360. 2019 - Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study. Journal of Cutaneous Medicine and Surgery. 23:282-288. 2019
- Clinical Goals and Barriers to Effective Psoriasis Care. Dermatology and Therapy. 9:5-18. 2019
- Cohort Using a Ceramides Containing Cleanser and Cream With Salicylic Acid for Dry, Flaking, and Scaling Skin Conditions.. Journal of Drugs in Dermatology. 18:80-85. 2019
- Ixekizumab improves patient-reported outcomes in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: SPIRIT-P2 results to 52 weeks.. Clinical and Experimental Rheumatology. 37:566-574. 2019
- Psoriasis patients’ preference for an aerosol foam topical formulation. Journal of the European Academy of Dermatology and Venereology. 32:e400-e401. 2018
- Canadian Patients’ Preferences in Topical Psoriasis Care: Insights From the PROPEL Surveys. Journal of Cutaneous Medicine and Surgery. 22:464-471. 2018
- Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. Journal of American Academy of Dermatology. 78:741-748. 2018
- Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies. Dermatology and Therapy. 8:17-32. 2018
- Survival of the fittest. British Journal of Dermatology. 178:328-329. 2018
- A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults. Journal of Cutaneous Medicine and Surgery. 22:78-83. 2018
- Undergraduate Dermatology Education in Canada: A National Survey. Journal of Cutaneous Medicine and Surgery. 22:31-37. 2018
- Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. British Journal of Dermatology. 177:1495-1502. 2017
- Acitretin Use in Dermatology. Journal of Cutaneous Medicine and Surgery. 21:2S-12S. 2017
- Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition. Journal of Cutaneous Medicine and Surgery. 21:2S-40S. 2017
- Biosimilars for psoriasis: clinical studies to determine similarity. British Journal of Dermatology. 177:23-33. 2017
- An Open Letter to Health Canada. Journal of Cutaneous Medicine and Surgery. 21:195-196. 2017
- Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice. Journal of Rheumatology. 44:519-534. 2017
- Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. 31:323-332. 2017
- Review of Systemic Treatment Options for Adult Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery. 21:31-39. 2017
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. Journal of American Academy of Dermatology. 76:60-69.e9. 2017
- 2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009. Journal of Cutaneous Medicine and Surgery. 20:375-431. 2016
- Acral Hemorrhagic Darier’s Disease. Journal of Cutaneous Medicine and Surgery. 20:478-480. 2016
- Transitioning Between Brodalumab and Secukinumab in Moderate to Severe Psoriasis: An Early Look.. Journal of Drugs in Dermatology. 15:941-943. 2016
- Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis.. Journal of Clinical and Aesthetic Dermatology. 9:S12-S16. 2016
- Psoronychomycosis. Journal of Cutaneous Medicine and Surgery. 20:279-280. 2016
- Biosimilars for psoriasis: preclinical analytical assessment to determine similarity. British Journal of Dermatology. 174:282-286. 2016
- Non-melanoma Skin Cancer in Canada Chapter 2: Primary Prevention of Non-melanoma Skin Cancer (vol 19, pg 216, 2015). Journal of Cutaneous Medicine and Surgery. 19:604-604. 2015
- Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses (vol 19, 227, 2015). Journal of Cutaneous Medicine and Surgery. 19:604-604. 2015
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. The Lancet. 386:541-551. 2015
- Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab. Journal of the European Academy of Dermatology and Venereology. 29:1576-1581. 2015
- Non-melanoma Skin Cancer in Canada Chapter 1: Introduction to the Guidelines. Journal of Cutaneous Medicine and Surgery. 19:205-215. 2015
- Non-melanoma Skin Cancer in Canada Chapter 2: Primary Prevention of Non-melanoma Skin Cancer. Journal of Cutaneous Medicine and Surgery. 19:216-226. 2015
- Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses. Journal of Cutaneous Medicine and Surgery. 19:227-238. 2015
- Non-melanoma Skin Cancer in Canada Chapter 4: Management of Basal Cell Carcinoma. Journal of Cutaneous Medicine and Surgery. 19:239-248. 2015
- Non-melanoma Skin Cancer in Canada Chapter 5: Management of Squamous Cell Carcinoma. Journal of Cutaneous Medicine and Surgery. 19:249-259. 2015
- Paradoxical, Cupping-Induced Localized Psoriasis: A Koebner Phenomenon. Journal of Cutaneous Medicine and Surgery. 19:320-322. 2015
- Public Engagement with Dermatology Contents on Facebook. Journal of Cutaneous Medicine and Surgery. 19:304-308. 2015
- Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). British Journal of Dermatology. 172:484-493. 2015
- Think beyond the Skin. Journal of Cutaneous Medicine and Surgery. 19:22-27. 2015
- A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin. British Journal of Dermatology. 171:1508-1516. 2014
- Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials.. Journal of Drugs in Dermatology. 13:1380-1386. 2014
- Use of Facebook as a Tool for Knowledge Dissemination in Dermatology. Journal of Cutaneous Medicine and Surgery. 18:341-344. 2014
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials. New England Journal of Medicine. 371:326-338. 2014
- A Consensus on Acne Management Focused on Specific Patient Features. Journal of Cutaneous Medicine and Surgery. 18:243-255. 2014
- Interleukin 17A: Toward a new understanding of psoriasis pathogenesis. Journal of American Academy of Dermatology. 71:141-150. 2014
- Moisturizers and Ceramide-containing Moisturizers May Offer Concomitant Therapy with Benefits.. Journal of Clinical and Aesthetic Dermatology. 7:18-26. 2014
- Clinical features of external genital warts.. Journal of Cutaneous Medicine and Surgery. 17 Suppl 2:S55-S60. 2013
- Managing external genital warts: practical aspects of treatment and prevention.. Journal of Cutaneous Medicine and Surgery. 17 Suppl 2:S68-S75. 2013
- Therapeutic options for external genital warts.. Journal of Cutaneous Medicine and Surgery. 17 Suppl 2:S61-S67. 2013
- Understanding genital warts: epidemiology, pathogenesis, and burden of disease of human papillomavirus.. Journal of Cutaneous Medicine and Surgery. 17 Suppl 2:S47-S54. 2013
- Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.. Journal of Drugs in Dermatology. 12:1122-1129. 2013
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. The Lancet. 382:780-789. 2013
- One-Year, Multicenter, Open-Label, Single-Arm Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Moderate-to-Severe Plaque Psoriasis in a Canadian Population. Journal of Cutaneous Medicine and Surgery. 17:129-138. 2013
- Sulfa or Sulfur? Clearing Things up. Journal of Cutaneous Medicine and Surgery. 17:79-81. 2013
- Etanercept Improves Quality of Life Outcomes and Treatment Satisfaction in Patients with Moderate to Severe Plaque Psoriasis in Clinical Practice. Journal of Cutaneous Medicine and Surgery. 16:407-416. 2012
- Etanercept Improves Quality of Life Outcomes and Treatment Satisfaction in Patients with Moderate to Severe Plaque Psoriasis in Clinical Practice. Journal of Cutaneous Medicine and Surgery. 16:407-416. 2012
- Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis. Applied Health Economics and Health Policy. 10:343-353. 2012
- Comparison of Dermatologists' and Nondermatologists' Diagnostic Accuracy for Malignant Melanoma. Journal of Cutaneous Medicine and Surgery. 16:272-280. 2012
- Erythema ab igne caused by laptop computer gaming – a case report. International Journal of Dermatology. 51:716-717. 2012
- Double-Blinded, Vehicle-Controlled Proof of Concept Study to Investigate the Recurrence of Inflammatory and Noninflammatory Acne Lesions Using Tretinoin Gel (Microsphere) 0.04% in Male Patients after Oral Isotretinoin Use. Dermatology Research and Practice. 2012:1-5. 2012
- Topical Psoriasis Therapy in the Age of Biologics: Evidence-Based Treatment Recommendations. Journal of Cutaneous Medicine and Surgery. 15:309-321. 2011
- Newer approaches in topical combination therapy for acne.. Skin therapy letter. 16:3-6. 2011
- Canadian Guidelines for the Management of Plaque Psoriasis: Overview. Journal of Cutaneous Medicine and Surgery. 15:210-219. 2011
- Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet. JAMA dermatology. 147:429-429. 2011
- An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.. Journal of Drugs in Dermatology. 10:396-402. 2011
- Gourmet Clinical Pearls. Journal of Cutaneous Medicine and Surgery. 15:63-64. 2011
- Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study. European Journal of Dermatology. 21:89-94. 2011
- Systemic Role for Vitamin D in the Treatment of Psoriasis and Metabolic Syndrome. Dermatology Research and Practice. 2011:1-4. 2011
- Drug-Induced Lichenoid Dermatitis with Histopathologic Features of Mycosis Fungoides in a Patient with Psoriasis. Journal of Cutaneous Medicine and Surgery. 14:307-309. 2010
- Adapalene 0.1% lotion in the treatment of acne vulgaris: results from two placebo-controlled, multicenter, randomized double-blind, clinical studies.. Journal of Drugs in Dermatology. 9:639-646. 2010
- Are Excipients Really Inert Ingredients? A Review of Adverse Reactions to Excipients in Oral Dermatologic Medications in Canada. Journal of Cutaneous Medicine and Surgery. 14:105-114. 2010
- Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis. Journal of Dermatological Treatment. 21:185-192. 2010
- Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis.. Cutis. 85:43-50. 2010
- Efficacy Outcomes in Patients Using Alefacept in the AWARE Study. Journal of Cutaneous Medicine and Surgery. 13:S122-S130. 2009
- Adalimumab in the Treatment of Psoriasis: Pooled Efficacy and Safety Results from Three Pivotal Studies. Journal of Cutaneous Medicine and Surgery. 13:S58-S66. 2009
- Biologic survival.. Journal of Drugs in Dermatology. 8:329-333. 2009
- Short-contact clobetasol propionate shampoo 0.05% improves quality of life in patients with scalp psoriasis.. Cutis. 83:157-164. 2009
- Nail Psoriasis and Biologics. Journal of Cutaneous Medicine and Surgery. 13:1-5. 2009
- Occurrence of Plantar Pustular Psoriasis during Treatment with Infliximab. Journal of Cutaneous Medicine and Surgery. 13:40-42. 2009
- Treatment of severe facial psoriasis with adalimumab.. Journal of Drugs in Dermatology. 7:1165-1167. 2008
- Practical Understanding of Mean Percent Psoriasis Area and Severity Index Reduction for Biologics. Journal of Cutaneous Medicine and Surgery. 12:282-287. 2008
- Are All Seborrheic Keratoses Benign? Review of the Typical Lesion and Its Variants. Journal of Cutaneous Medicine and Surgery. 12:203-210. 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). The Lancet. 371:1675-1684. 2008
- Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial. British Journal of Dermatology. 158:1083-1093. 2008
- Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy. Journal of American Academy of Dermatology. 57:1-27. 2007
- Management and treatment of pruritus.. Skin therapy letter. 12:1-6. 2007
- Miliarial Gout (A New Entity). Journal of Cutaneous Medicine and Surgery. 11:31-34. 2007
- Multitherapy Approach to Onychomycosis Therapy. Journal of Cutaneous Medicine and Surgery. 10:S44-S47. 2006
- Prevalence and Epidemiology of Onychomycosis. Journal of Cutaneous Medicine and Surgery. 10:S28-S33. 2006
- Cutaneous Reaction to Drugs Used for Erectile Dysfunction: Case Report and Review of the Literature. Journal of Cutaneous Medicine and Surgery. 10:128-130. 2006
- Use of Calcipotriene Cream (Dovonex?? Cream) Following Acute Treatment of Psoriasis Vulgaris with the Calcipotriene/Betamethasone Dipropionate Two-Compound Product (Taclonex??). American Journal of Clinical Dermatology. 7:177-184. 2006
- Innovative uses of imiquimod.. Journal of Drugs in Dermatology. 4:58-63. 2005
- The treatment of atopic dermatitis and other dermatoses with leukotriene antagonists.. Skin therapy letter. 9:1-5. 2004
- Antihistamines in the Treatment of Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery. 7:467-473. 2003
- Antihistamines in the Treatment of Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery. 7:467-473. 2003
- Adverse reactions to herbal therapy in dermatology.. Skin therapy letter. 8:5-8. 2003
- The utility of patch testing children with atopic dermatitis.. Skin therapy letter. 7:4-6. 2002
- Alternative treatments for atopic dermatitis: a selected review.. Skin therapy letter. 7:1-5. 2002